Intervention Review

Atypical antipsychotics for aggression and psychosis in Alzheimer's disease

  1. Clive G Ballard1,*,
  2. Jonathan Waite2,
  3. Jacqueline Birks3

Editorial Group: Cochrane Dementia and Cognitive Improvement Group

Published Online: 25 JAN 2006

Assessed as up-to-date: 21 FEB 2006

DOI: 10.1002/14651858.CD003476.pub2


How to Cite

Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD003476. DOI: 10.1002/14651858.CD003476.pub2.

Author Information

  1. 1

    Kings College London, The Wolfson Centre for Age-Related Diseases, London, UK

  2. 2

    The Courtyard, Old Age Psychiatary, Nottingham, UK

  3. 3

    University of Oxford, Centre for Statistics in Medicine, Oxford, UK

*Clive G Ballard, The Wolfson Centre for Age-Related Diseases, Kings College London, The Wolfson Wing, Hodgkin Building, Guy's Campus, London, SE1 1UL, UK. clive.ballard@kcl.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 25 JAN 2006

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Marcin Kołaczkowski, Paweł Mierzejewski, Przemyslaw Bienkowski, Anna Wesołowska, Adrian Newman-Tancredi, Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia, Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 6, 545

    CrossRef

  2. 2
    Lucy Y. Wang, Anna Borisovskaya, Andrea L. Maxwell, Marcella Pascualy, Common Psychiatric Problems in Cognitively Impaired Older Patients, Clinics in Geriatric Medicine, 2014, 30, 3, 443

    CrossRef

  3. 3
    Romika Dhar, Lou Ann Eads, Current Concepts Relative to the Appropriate Use of Antipsychotics in the Elderly, Current Geriatrics Reports, 2014, 3, 4, 253

    CrossRef

  4. 4
    Veronique Verhoeven, Maja Lopez Hartmann, Johan Wens, Bernard Sabbe, Peter Dieleman, Giannoula Tsakitzidis, Paul Van Royen, Roy Remmen, Happy pills in nursing homes in Belgium: A cohort study to determine prescribing patterns and relation to fall risk, Journal of Clinical Gerontology and Geriatrics, 2014, 5, 2, 53

    CrossRef

  5. 5
    Susan E. Merel, Shaune DeMers, Elizabeth Vig, Palliative Care in Advanced Dementia, Clinics in Geriatric Medicine, 2014, 30, 3, 469

    CrossRef

  6. 6
    Deepa Acharya, David G. Harper, Eric D. Achtyes, Stephen J. Seiner, Jack A. Mahdasian, Louis J. Nykamp, Lesley Adkison, Lori Van der Schuur White, Shawn M. McClintock, Manjola Ujkaj, Donald A. Davidoff, Brent P. Forester, Safety and utility of acute electroconvulsive therapy for agitation and aggression in dementia, International Journal of Geriatric Psychiatry, 2014, 29, 12
  7. 7
    Adeline Gallini, Sandrine Andrieu, Julie M. Donohue, Naïma Oumouhou, Maryse Lapeyre-Mestre, Virginie Gardette, Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings, European Neuropsychopharmacology, 2014, 24, 1, 95

    CrossRef

  8. 8
    David M Gardner, Andrea L Murphy, Stan Kutcher, Serge Beaulieu, Carlo Carandang, Alain Labelle, Pierre Lalonde, Ashok Malla, Heather Milliken, Claire O’Donovan, Ayal Schaffer, Jorge Soni, Valerie H Taylor, Richard Williams, Evidence review and clinical guidance for the use of ziprasidone in Canada, Annals of General Psychiatry, 2013, 12, 1, 1

    CrossRef

  9. 9
    Hanne Mette O. Ridder, Brynjulf Stige, Liv Gunnhild Qvale, Christian Gold, Individual music therapy for agitation in dementia: an exploratory randomized controlled trial, Aging & Mental Health, 2013, 17, 6, 667

    CrossRef

  10. 10
    Nicole J. Brandt, Jessica Pyhtila, Psychopharmacological Medication Use Among Older Adults with Dementia in Nursing Homes, Journal of Gerontological Nursing, 2013, 39, 4, 8

    CrossRef

  11. 11
    Katrina Weston-Green, Xu-Feng Huang, Chao Deng, Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor, CNS Drugs, 2013, 27, 12, 1069

    CrossRef

  12. 12
    Eric Widera, Kenneth E. Covinsky, Evidence-Based Practice in Palliative Medicine, 2013,

    CrossRef

  13. 13
    Anne Child, Amy Clarke, Chris Fox, Ian Maidment, A pharmacy led program to review anti-psychotic prescribing for people with dementia, BMC Psychiatry, 2012, 12, 1, 155

    CrossRef

  14. 14
    Jennifer Tjia, Jerry H. Gurwitz, Becky A. Briesacher, Challenge of Changing Nursing Home Prescribing Culture, The American Journal of Geriatric Pharmacotherapy, 2012, 10, 1, 37

    CrossRef

  15. 15
    Massimo Gallerani, Davide Imberti, Elisa Mari, Anna Marra, Roberto Manfredini, Risperidone and pulmonary embolism: a harmful association? Case series and review of the literature, Acta Neuropsychiatrica, 2012, 24, 6
  16. 16
    Majda Azermai, Mirko Petrovic, Monique M. Elseviers, Jolyce Bourgeois, Luc M. Van Bortel, Robert H. Vander Stichele, Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms, Ageing Research Reviews, 2012, 11, 1, 78

    CrossRef

  17. 17
    Albert Diefenbacher, Ronald Burian, Christian Klesse, Martin Härter, Psychische Erkrankungen, 2012,

    CrossRef

  18. 18
    Michael Hüll, Hans Förstl, Psychische Erkrankungen, 2012,

    CrossRef

  19. 19
    David Lussier, Marie-Andrée Bruneau, Juan Manuel Villalpando, Management of End-Stage Dementia, Primary Care: Clinics in Office Practice, 2011, 38, 2, 247

    CrossRef

  20. 20
    M. Llanero Luque, J.M. Ruiz Sánchez de León, P. Medrano Izquierdo, C. Fernández García, Tratamiento de la enfermedad de Alzheimer, Medicine - Programa de Formación Médica Continuada Acreditado, 2011, 10, 76, 5138

    CrossRef

  21. 21
    Pilar Hereu, Antonio Vallano, Uso de antipsicóticos en pacientes con demencia, Revista Española de Geriatría y Gerontología, 2011, 46, 1, 50

    CrossRef

  22. 22
    P. Naarding, M. van Grevenstein, A. T. F. Beekman, Benefit–risk analysis for the clinician: ‘primum non nocere’ revisited—the case for antipsychotics in the treatment of behavioural disturbances in dementia, International Journal of Geriatric Psychiatry, 2010, 25, 5
  23. 23
    Prasad S. Nishtala, Andrew J. McLachlan, J. Simon Bell, Timothy F. Chen, Determinants of antipsychotic medication use among older people living in aged care homes in Australia, International Journal of Geriatric Psychiatry, 2010, 25, 5
  24. 24
    Paul T. Francis, María J. Ramírez, Mitchell K. Lai, Neurochemical basis for symptomatic treatment of Alzheimer's disease, Neuropharmacology, 2010, 59, 4-5, 221

    CrossRef

  25. 25
    J. A. Tsiouris, Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?, Journal of Intellectual Disability Research, 2010, 54, 1
  26. 26
    Javier Gómez-Pavón, Paloma González García, Inés Francés Román, Maite Vidán Astiz, José Gutiérrez Rodríguez, Gregorio Jiménez Díaz, Nuria Pilar Montero Fernández, Baldomero Álvarez Fernández, José María Jiménez Páez, Recomendaciones en la prevención de reacciones adversas a medicamentos en personas mayores con demencia, Revista Española de Geriatría y Gerontología, 2010, 45, 2, 89

    CrossRef

  27. 27
    Juanita Westbury, Karin Beld, Shane Jackson, Gregory Peterson, Review of psychotropic medication in Tasmanian residential aged care facilities, Australasian Journal on Ageing, 2010, 29, 2
  28. 28
    Mehrul Hasnain, W. Victor R. Vieweg, Mark S. Baron, Mary Beatty-Brooks, Antony Fernandez, Anand K. Pandurangi, Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism, The American Journal of Medicine, 2009, 122, 7, 614

    CrossRef

  29. 29
    Dirk K. Wolter, Risiken von Antipsychotika im Alter, speziell bei Demenzen<sup>1</sup>, Zeitschrift für Gerontopsychologie & -psychiatrie, 2009, 22, 1, 17

    CrossRef

  30. 30
    Clive Ballard, Maria Luisa Hanney, Megan Theodoulou, Simon Douglas, Rupert McShane, Katja Kossakowski, Randeep Gill, Edmund Juszczak, Ly-Mee Yu, Robin Jacoby, The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial, The Lancet Neurology, 2009, 8, 2, 151

    CrossRef

  31. 31
    Naomi Gronich, Darrell R. Abernethy, Pharmacology and Therapeutics, 2009,

    CrossRef

  32. 32
    Jiska Cohen-Mansfield, Barbara Jensen, Assessment and Treatment Approaches for Behavioral Disturbances Associated With Dementia in the Nursing Home: Self-Reports of Physicians' Practices, Journal of the American Medical Directors Association, 2008, 9, 6, 406

    CrossRef

  33. 33
    Clive Ballard, Jane Fossey, Clinical management of dementia, Psychiatry, 2008, 7, 2, 88

    CrossRef

  34. 34
    Larry E. Tune, Julie Rosenberg, Nonpharmacological Treatment of Inappropriate Sexual Behavior in Dementia: The Case of the Pink Panther, The American Journal of Geriatric Psychiatry, 2008, 16, 7, 612

    CrossRef

  35. 35
    Jean-François Locca, Christophe J. Büla, Serge Zumbach, Oliver Bugnon, Pharmacological Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) in Nursing Homes: Development of Practice Recommendations in a Swiss Canton, Journal of the American Medical Directors Association, 2008, 9, 6, 439

    CrossRef

  36. 36
    Sabine Ruths, Jørund Straand, Harald A. Nygaard, Dag Aarsland, Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study––The Bergen District Nursing Home Study (BEDNURS), International Journal of Geriatric Psychiatry, 2008, 23, 9
  37. 37
    Barbara J. Messinger-Rapport, John E. Morley, David R. Thomas, Julie K. Gammack, Intensive Session: New Approaches to Medical Issues in Long-Term Care, Journal of the American Medical Directors Association, 2007, 8, 7, 421

    CrossRef

  38. 38
    Joël Belmin, Renaud Péquignot, Cécile Konrat, Sylvie Pariel-Madjlessi, Prise en charge de la maladie d'Alzheimer, La Presse Médicale, 2007, 36, 10, 1500

    CrossRef

  39. 39
    Dallas P Seitz, Nikesh Adunuri, Sudeep S. Gill, Andrea Gruneir, Nathan Herrmann, Paula Rochon, Antidepressants for agitation and psychosis in dementia, The Cochrane Library,
  40. 40
    Dallas P Seitz, Nikesh Adunuri, Sudeep Gill, Andrea Gruneir, Nathan Herrmann, Paula Rochon, Antidepressants for agitation and psychosis in dementia, The Cochrane Library,
  41. 41
    Clive G Ballard, Jonathan Waite, Jacqueline Birks, Atypical antipsychotics for aggression and psychosis in Alzheimer's disease, The Cochrane Library,
  42. 42
    Sarada Krishnan, Ruth Cairns, Robert Howard, Cannabinoids for the treatment of dementia, The Cochrane Library,
  43. 43
    Sarada Krishnan, Ruth Cairns, Robert Howard, Cannabinoids for the treatment of dementia, The Cochrane Library,
  44. 44
    Richard Brown, Robert Howard, Bridget Candy, Elizabeth L Sampson, Opioids for agitation in dementia, The Cochrane Library,
  45. 45
    Tanja Richter, Gabriele Meyer, Ralph Möhler, Sascha Köpke, Psychosocial interventions for reducing antipsychotic medication in care home residents, The Cochrane Library,
  46. 46
    Uzair Ahmed, Faiz Rehman, Hannah Jones, Clive E Adams, Risperidone for psychosis induced aggression or agitation, The Cochrane Library,
  47. 47
    Tom Declercq, Mirko Petrovic, Robert Vander Stichele, An IM De Sutter, Mieke L van Driel, Thierry Christiaens, Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and neuropsychiatric symptoms in elderly patients with dementia, The Cochrane Library,
  48. 48
    Tom Declercq, Mirko Petrovic, Majda Azermai, Robert Vander Stichele, An IM De Sutter, Mieke L van Driel, Thierry Christiaens, Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia, The Cochrane Library,